Navigation Links
Hormone therapy for prostate cancer does not appear to increase cardiac deaths
Date:12/10/2008

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers. While a 2006 report from members of the same study team found that treatment with gonadotropin-releasing hormone (GnRH) agonists increased the risk of diabetes and heart disease, the current study is the first to examine whether treatment actually increased heart-disease-related deaths. In their Journal of Clinical Oncology report, which has been released online, the researchers note that GnRH agonist treatment has a number of adverse side effects, which should be kept in mind when determining treatment strategies.

"Hormonal therapy for prostate cancer has become routine for many patients, so it's even more important to understand the potential adverse effects of treatment," says lead author Jason Efstathiou, MD, PhD, of the MGH Cancer Center. "Given recent concerns about the safety and impact on cardiac health of hormonal therapies particularly GnRN agonists our study is quite timely."

Since the male hormones called androgens can accelerate the development of prostate cancer, reducing their activity is a standard part of treating the disease. Most commonly this is done with GnRH agonists that block the production of all sex hormones. GnRH agonist therapy is routinely administered to men whose cancer has spread beyond the prostate gland, and its use in patients whose tumors appear confined to the prostate is becoming more common. It is estimated that one-third of the two million prostate cancer survivors in the U.S. are currently receiving this therapy, making understanding the potential adverse effects of treatment particularly important.

The earlier report from a Harvard Medical School team including Matthew Smith, MD, PhD, of the MGH Cancer Center, who is corresponding author of the current study found that men with localized prostate cancer who received GnRH agonist therapy had a greater risk of developing diabetes or cardiovascular disease than patients not receiving hormonal treatment. To specifically investigate the relationship between GnRH agonist therapy and death from cardiovascular disease, the current study analyzed data from a 1987-92 clinical trial in which almost 1,000 patients were treated for locally advanced prostate cancer with either the GnRH agonist goserelin plus radiation therapy or radiation therapy alone.

During the decade following completion of the clinical trial, more than half the participants died from various causes. Of the 574 deaths, 117 were from cardiovascular disease, but whether or not patients had received the GnRH agonist apparently had no effect on the risk of cardiovascular death. Instead, it was established cardiac risk factors including heart disease or diabetes that existed prior to GnRH agonist treatment that appeared to increase the risk of dying from cardiovascular disease.

"The absence of an increase in cardiovascular mortality does not exclude the possibility that GnRH agonists increase non-cancer deaths through other mechanisms," Efstathiou stresses. "In addition to the increased risk for diabetes identified in the 2006 study, we know they can raise the risk of fractures and anemia both of which can reduce survival and can have adverse effects on weight gain, cholesterol levels, mood and sexual function.

"While our study supports the continued use of GnRH agonists in situations where the benefit for cancer control has been established typically the treatment of advanced or more aggressive prostate cancer clinicians should keep in mind the risks of diabetes and cardiovascular disease and help their patients adopt strategies to reduce those risks," he adds. "Further studies are needed to evaluate potential risks for men with earlier stage prostate cancer, for whom the role of GnRH agonists is not as well defined, and treatment decisions need to carefully weigh potential risks and benefits." Efstathiou is an instructor in Radiation Oncology at Harvard Medical School.


'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Drop in breast cancer incidence linked to hormone use, not mammograms
2. Researchers develop long-lasting growth hormone
3. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
4. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
5. Most Women Unaware of Hormone Replacement Study
6. Survival data presented from phase II study of hormone-resistant prostate cancer patients
7. Hormone May Play Key Part in Creating Memories
8. Hormone Therapy for Prostate Cancer Linked to Heart Risks
9. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
10. New data on hormone therapy must lead to re-evaluation of official guidelines
11. From Hot Flashes to Breast Cancer: ZRT Labs Hormone Testing Catches On As Women Consider Safer, More Natural Options.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... , ... February 26, 2017 , ... ... for entries to the 7th Edition of International Social Design Awards. , ... Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects and ...
(Date:2/26/2017)... Philadelphia, PA (PRWEB) , ... February 26, 2017 , ... ... products and services with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for ... , Robert Hennessey, the founder of IndustryArchive.Org, said, “Given the new reality that B2B ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is ... University predict that 47 percent of all jobs in the United States may be ... “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing to ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Following receiving CE Marking in ... s AMAR is a major milestone for the country where the ... ound care market in Israel ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment ...
(Date:2/24/2017)... and Markets has announced the addition of the "Hemophilia Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Hemophilia ... market? What are the unit prices and annual treatment ...
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
Breaking Medicine Technology: